Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VX 5

Next Previous
X
Search
Drug Profile

VX 5

Alternative Names: Anti-CXCL13 antibody; Anti-CXCL13 monoclonal antibody; VX-5; VX5/5261; VX5/5261-muIg

Latest Information Update: 17 Apr 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vaccinex
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Chemokine CXCL13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer; Encephalomyelitis; Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 17 Apr 2024 VX 5 is available for licensing as of 17 Apr 2024. (https://www.vaccinex.com/pipeline/)
  • 28 Jan 2023 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Intraperitoneal)
  • 28 Jan 2023 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA (Intraperitoneal)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top